| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Dec'18 | Sep'18 | Jun'18 | Mar'18 | Dec'17 | Sep'17 | Jun'17 | Mar'17 | Sep'16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | |||||||||||||
Grant revenue | |||||||||||||
1,532 | 2,934 | 4,471 | 2,089 | 3,911 | 1,692 | 658 | 463 | 1,153 | - | - | - | - | - |
Collaboration revenue | |||||||||||||
169 | 696 | 172 | 67 | 3,807 | - | - | - | - | - | - | - | - | - |
Total revenues | |||||||||||||
1,701 | 3,630 | 4,643 | 2,156 | 7,718 | 1,692 | 658 | 463 | 1,153 | - | 597 | 249 | - | - |
Grant revenue | |||||||||||||
- | - | - | - | - | - | - | - | - | - | - | - | 140 | - |
Operating expenses: | |||||||||||||
Research and development | |||||||||||||
20,436 | 25,728 | 18,495 | 12,026 | 9,526 | 9,127 | 8,459 | 7,374 | 8,925 | 12,503 | 6,910 | 7,457 | 5,999 | 6,005 |
General and administrative | |||||||||||||
4,086 | 3,785 | 4,133 | 3,782 | 3,888 | 3,649 | 3,134 | 3,060 | 3,044 | 2,490 | 3,653 | 2,957 | 1,740 | 1,909 |
Total operating expenses | |||||||||||||
24,522 | 29,513 | 22,628 | 15,808 | 13,414 | 12,776 | 11,593 | 10,434 | 11,969 | 14,993 | 10,563 | 10,414 | 7,739 | 7,914 |
Loss from operations | |||||||||||||
-22,821 | -25,883 | -17,985 | -13,652 | -5,696 | -11,084 | -10,935 | -9,971 | -10,816 | -14,000 | -9,966 | -10,165 | -7,599 | -7,914 |
Other income (expense): | |||||||||||||
Interest income | |||||||||||||
237 | - | - | - | 239 | - | - | - | - | - | - | - | - | - |
Change in fair value of derivative liabilities | |||||||||||||
- | - | - | - | - | - | - | - | - | 3,088 | 2 | -350 | -1,199 | 4 |
Interest income and other income (expense), net | |||||||||||||
- | - | 268 | 502 | - | - | 472 | 15 | 172 | 138 | 124 | 52 | -11 | - |
Other income (expense), net | |||||||||||||
-674 | -415 | 268 | 502 | 385 | -616 | 472 | 15 | 172 | 132 | 122 | 402 | 1,188 | -4 |
Total other income (expense), net | |||||||||||||
-437 | - | - | - | 624 | - | - | - | - | - | - | - | - | - |
Net loss | |||||||||||||
-23,258 | -24,986 | -17,717 | -13,150 | -5,072 | -10,599 | -10,463 | -9,956 | -10,644 | -13,868 | -9,844 | -9,763 | -6,411 | -7,918 |
Less: Net loss attributable to non-controlling interest | |||||||||||||
- | - | - | - | - | - | - | - | - | -6 | -8 | -594 | -535 | -1,602 |
Net loss attributable to Spero Therapeutics, Inc. | |||||||||||||
- | - | - | - | - | - | - | - | - | -13,862 | -9,836 | -9,169 | -5,876 | -6,316 |
Cumulative dividends on redeemable convertible preferred shares | |||||||||||||
- | - | - | - | - | - | - | - | - | 833 | 2,052 | 2,025 | 1,236 | 916 |
Accretion of redeemable bridge units and redeemable convertible preferred shares to redemption value | |||||||||||||
- | - | - | - | - | - | - | - | - | 75 | 188 | 927 | 18 | 178 |
Net loss attributable to common shareholders of Spero Therapeutics, Inc. | |||||||||||||
- | - | - | - | - | - | - | - | - | -14,770 | -12,076 | -12,121 | -7,130 | -7,410 |
Net loss per share attributable to common stockholders, basic and diluted | |||||||||||||
-1.22 | -1.37 | -0.95 | -0.74 | -0.29 | -0.57 | -0.60 | -0.69 | -0.74 | 76.01 | -36.02 | -36.21 | -21.60 | -23.23 |
Weighted average common shares outstanding, basic and diluted: | |||||||||||||
19,557 | 19,094 | 18,659 | 17,667 | 17,221 | 17,790 | 17,471 | 14,376 | 14,369 | 9,347 | 335 | 334 | 330 | 318 |
Comprehensive loss: | |||||||||||||
Net loss | |||||||||||||
-23,258 | -24,986 | -17,717 | -13,150 | -5,072 | -10,599 | -10,463 | -9,956 | -10,644 | -13,868 | -9,844 | -9,763 | -6,411 | - |
Other comprehensive gain (loss): | |||||||||||||
Unrealized gain (loss) on marketable securities | |||||||||||||
-35 | -2 | 12 | 5 | 23 | -5 | -8 | 14 | -29 | - | - | - | - | - |
Reclassification adjustment for gains included in net loss | |||||||||||||
- | 0 | 0 | 0 | -6 | - | - | - | - | - | - | - | - | - |
Net unrealized gains (losses) on securities | |||||||||||||
-35 | -2 | 12 | 5 | 29 | -5 | -8 | 14 | -29 | - | - | - | - | - |
Total comprehensive loss | |||||||||||||
-23,293 | -24,988 | -17,705 | -13,145 | -5,043 | -10,604 | -10,471 | -9,942 | -10,673 | -13,868 | -9,844 | -9,763 | -6,411 | - |